Immunoembolization Outcomes for Liver Metastatic Uveal Melanoma, 2010-2023

43 patients underwent 249 immunoembolization procedures for liver-dominant metastatic uveal melanoma at a single center between 2010 and 2023. The dataset includes demographics, tumor characteristics, treatment details, and outcomes such as disease control rate, progression-free survival, and overall survival. This retrospective analysis was authored by Renee Morecroft and shared under a CC-BY-4.0 license.

Use Cases

• Compare survival outcomes (OS, PFS) between immunoembolization and other regional therapies like melphalan perfusion.
• Analyze the sequencing effect of prior systemic therapy on immunoembolization treatment response.
• Model disease control rates (DCR) based on patient demographics and tumor characteristics.
• Conduct subgroup survival analysis for patients with liver-only versus extrahepatic metastases.

Strengths

• Includes detailed outcome metrics for 43 patients over a 13-year period (2010-2023).
• Provides comparative data against a Phase 3 clinical trial (FOCUS trial).
• Contains subgroup analysis based on prior systemic therapy exposure (n=12 vs. treatment-naïve).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data reflects a single-center, retrospective study with a homogeneous patient cohort (all Caucasian).

Provenance

Source

figshare

Collection Method

Single-center retrospective review of clinical records.

Time Range

2010 to 2023

Freshness

Last updated 2026-04 23 04:19:56; freshness should be verified.

Geography

null